Identification of Clinical and Pharmacogenetic Factors Predictive of Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
Most Recent Events
- 05 Jun 2023 Planned primary completion date changed from 31 Mar 2023 to 30 Sep 2023.
- 05 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2023 Planned End Date changed from 31 Oct 2022 to 30 Sep 2023.